![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 56, Issue 6, 1105-1115, December 1999
Istituto di Biologia Cellulare, "Campus Adriano
Buzzati-Traverso" Consiglio Nazionale delle Ricerche, Rome, Italy
(P.F., J.F.A., A.S., R.H.B., P.B.); and Department of Pharmaceutical
Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
(M.-A.B.)
DNA topoisomerase I (Top1p) relaxes supercoiled DNA by the
formation of a covalent intermediate in which the active site tyrosine is transiently bound to the severed DNA strand. The antineoplastic agent camptothecin (Cpt) specifically targets Top1p and several mutations have been isolated that render the enzyme Cpt resistant. The
mutated residues, although located in different regions of the enzyme,
may constitute part of the Cpt binding site. To begin identifying the
structural features of DNA Top1p important for Cpt-induced
cytotoxicity, we developed a novel yeast genetic screen to isolate
catalytically active, yet Cpt-resistant enzymes from a pool of human
top1 mutants. Among the mutations isolated were substitutions of Ser or Val for Gly363, which like the Gly363 to Cys
mutation previously reported by us, suppressed the Cpt sensitivity of
Top1p. In contrast, each amino-acid substitution differed in its
ability to suppress the lethal phenotype and catalytic activity of a
human top1 mutant top1T718A that resembles Cpt by stabilizing the covalent intermediate. Biochemical analyses and molecular modeling support a model where interactions between two
conserved domains, a central "lip" region containing residue Gly363
and the residues around the active site tyrosine (Tyr723), directly
affect the formation of the Cpt-binding site and enzyme catalysis.
This article has been cited by other articles:
|
|
 |
|
  G. Chillemi, I. D'Annessa, P. Fiorani, C. Losasso, P. Benedetti, and A. Desideri Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations Nucleic Acids Res., October 1, 2008; 36(17): 5645 - 5651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van der Merwe and M.-A. Bjornsti Mutation of Gly721 Alters DNA Topoisomerase I Active Site Architecture and Sensitivity to Camptothecin J. Biol. Chem., February 8, 2008; 283(6): 3305 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Losasso, E. Cretaio, K. Palle, L. Pattarello, M.-A. Bjornsti, and P. Benedetti Alterations in Linker Flexibility Suppress DNA Topoisomerase I Mutant-induced Cell Lethality J. Biol. Chem., March 30, 2007; 282(13): 9855 - 9864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fiorani, G. Chillemi, C. Losasso, S. Castelli, and A. Desideri The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant Nucleic Acids Res., October 6, 2006; 34(18): 5093 - 5100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Jacquiau, R. C. A. M. van Waardenburg, R. J. D. Reid, M. H. Woo, H. Guo, E. S. Johnson, and M.-A. Bjornsti Defects in SUMO (Small Ubiquitin-related Modifier) Conjugation and Deconjugation Alter Cell Sensitivity to DNA Topoisomerase I-induced DNA Damage J. Biol. Chem., June 24, 2005; 280(25): 23566 - 23575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chillemi, P. Fiorani, S. Castelli, A. Bruselles, P. Benedetti, and A. Desideri Effect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics study Nucleic Acids Res., June 8, 2005; 33(10): 3339 - 3350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Colley, M. van der Merwe, J. R. Vance, A. B. Burgin Jr., and M.-A. Bjornsti Substitution of Conserved Residues within the Active Site Alters the Cleavage Religation Equilibrium of DNA Topoisomerase I J. Biol. Chem., December 24, 2004; 279(52): 54069 - 54078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chillemi, M. Redinbo, A. Bruselles, and A. Desideri Role of the Linker Domain and the 203-214 N-Terminal Residues in the Human Topoisomerase I DNA Complex Dynamics Biophys. J., December 1, 2004; 87(6): 4087 - 4097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fiorani, R. J. D. Reid, A. Schepis, H. R. Jacquiau, H. Guo, P. Thimmaiah, P. Benedetti, and M.-A. Bjornsti The Deubiquitinating Enzyme Doa4p Protects Cells from DNA Topoisomerase I Poisons J. Biol. Chem., May 14, 2004; 279(20): 21271 - 21281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Interthal, P. M. Quigley, W. G. J. Hol, and J. J. Champoux The Role of Lysine 532 in the Catalytic Mechanism of Human Topoisomerase I J. Biol. Chem., January 23, 2004; 279(4): 2984 - 2992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Woo, C. Losasso, H. Guo, L. Pattarello, P. Benedetti, and M.-A. Bjornsti Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality PNAS, November 25, 2003; 100(24): 13767 - 13772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Antony, M. Jayaraman, G. Laco, G. Kohlhagen, K. W. Kohn, M. Cushman, and Y. Pommier Differential Induction of Topoisomerase I-DNA Cleavage Complexes by the Indenoisoquinoline MJ-III-65 (NSC 706744) and Camptothecin: Base Sequence Analysis and Activity against Camptothecin- Resistant Topoisomerases I Cancer Res., November 1, 2003; 63(21): 7428 - 7435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fiorani, A. Bruselles, M. Falconi, G. Chillemi, A. Desideri, and P. Benedetti Single Mutation in the Linker Domain Confers Protein Flexibility and Camptothecin Resistance to Human Topoisomerase I J. Biol. Chem., October 31, 2003; 278(44): 43268 - 43275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chillemi, P. Fiorani, P. Benedetti, and A. Desideri Protein concerted motions in the DNA-human topoisomerase I complex Nucleic Acids Res., March 1, 2003; 31(5): 1525 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Staker, K. Hjerrild, M. D. Feese, C. A. Behnke, A. B. Burgin Jr., and L. Stewart The mechanism of topoisomerase I poisoning by a camptothecin analog PNAS, November 26, 2002; 99(24): 15387 - 15392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yang and J. J. Champoux Reconstitution of Enzymatic Activity by the Association of the Cap and Catalytic Domains of Human Topoisomerase I J. Biol. Chem., August 16, 2002; 277(34): 30815 - 30823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Woo, J. R. Vance, A. R. O. Marcos, C. Bailly, and M.-A. Bjornsti Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin J. Biol. Chem., February 1, 2002; 277(6): 3813 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fertala, J. R. Vance, P. Pourquier, Y. Pommier, and M.-A. Bjornsti Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate J. Biol. Chem., May 12, 2000; 275(20): 15246 - 15253. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
